Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)

Data as of Jan 28
 -1.48 / -6.01%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It is engaged in the development and commercialization of innovative, life-altering therapies for patients with debilitating and often fatal rare diseases. The company's lead product, lomitapide, is a small molecule, oral therapy to treat severe lipid disorders for an orphan patient population. The company was founded by David I. Scheer and William H. Lewis on February 4, 2005 and is headquartered in Cambridge, MA.

Contact Information

Aegerion Pharmaceuticals, Inc.
101 Main Street
Cambridge Massachusetts 02142-1519
P:(617) 500-7867
Investor Relations:
(617) 242-5028



Other institutional82.61%
Mutual fund holders51.70%
Individual stakeholders38.82%

Top Executives

Marc D. BeerChief Executive Officer & Director
Craig E. FraserChief Operating Officer
Mark J. FitzpatrickChief Financial Officer
Diane L. TribbleChief Scientific Officer
Mark SumerayChief Medical Officer

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.